Since HE4 serum levels correlate with cisplatin resistance in ovarian cancer patients [7–10], and our previous data suggested that HE4 promotes chemotherapy resistance in vitro and in vivo [7], we set out to further define the chemotherapy response of ovarian cancer cells that overexpress HE4. This evidence concerns the gene WFDC2 and ovarian cancer.